{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T23:12:18Z","timestamp":1772752338664,"version":"3.50.1"},"reference-count":6,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100014941","name":"Cytokinetics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014941","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.msard.2018.10.015","type":"journal-article","created":{"date-parts":[[2018,10,22]],"date-time":"2018-10-22T12:15:08Z","timestamp":1540210508000},"page":"131-132","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Lambert\u2013Eaton myasthenic syndrome associated with alemtuzumab administration"],"prefix":"10.1016","volume":"27","author":[{"given":"B. Mark","family":"Hoffman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuhad Abou","family":"Zeid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umar","family":"Alam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5814-6083","authenticated-orcid":false,"given":"James B.","family":"Caress","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2018.10.015_bib0001","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1056\/NEJMoa0802670","article-title":"Alemtuzumab vs. interferon beta-1a in early multiple sclerosis","volume":"359","author":"Coles","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2018.10.015_bib0002","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1212\/WNL.0b013e318228bec5","article-title":"Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort","volume":"77","author":"Cossburn","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2018.10.015_bib0003","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/j.1365-2567.2009.03115.x","article-title":"Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model","volume":"128","author":"Hu","year":"2009","journal-title":"Immunology"},{"key":"10.1016\/j.msard.2018.10.015_bib0004","first-page":"2052","article-title":"IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H)","volume":"119","author":"Jones","year":"2009","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.msard.2018.10.015_bib0005","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ejca.2017.05.041","article-title":"Myasthenia gravis: an emerging toxicity of immune checkpoint inhibitors","volume":"82","author":"Makarious","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.msard.2018.10.015_bib0006","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jneuroim.2008.03.002","article-title":"Regulatory T cells in paraneoplastic neurological syndromes","volume":"196","author":"Tani","year":"2008","journal-title":"J. Neuroimmunol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034818303778?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034818303778?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:46:53Z","timestamp":1761900413000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034818303778"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":6,"alternative-id":["S2211034818303778"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2018.10.015","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lambert\u2013Eaton myasthenic syndrome associated with alemtuzumab administration","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2018.10.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}